At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
Ramucirumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy
In Brief
A Phase 1 clinical trial evaluating Ramucirumab, Necitumumab, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 29 participants across 11 sites in 5 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesFrance, South Korea, Spain, Taiwan, United States
CollaboratorsAstraZeneca
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartOct 2016
Primary CompletionOct 2017
Study CompletionMay 2022
TodayJul 2026
First PostedJun 3, 2016
Enrollment StartOct 24, 2016
Primary CompletionOct 19, 2017
Study CompletionMay 9, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.1 years ago
Interventions
Ramucirumabdrug
Administered IV
Necitumumabdrug
Administered IV
Osimertinibdrug
Administered orally